がん用バイオマーカーの世界市場予測(~2022年):タンパク質バイオマーカー、遺伝子バイオマーカー

◆英語タイトル:Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022
◆発行会社/調査会社:MarketsandMarkets
◆商品コード:MAM-MD-5627
◆発行日:2017年10月5日
◆調査対象地域:グローバル
◆産業分野:医療機器
◆ページ数:269
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名利用)USD7,150 ⇒換算¥807,950見積依頼/購入/質問フォーム
Multi User (Five User)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
Corporate License (同一法人内共有可)USD9,150 ⇒換算¥1,033,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[がん用バイオマーカーの世界市場予測(~2022年):タンパク質バイオマーカー、遺伝子バイオマーカー]についてメールでお問い合わせはこちら
MarketsandMarketsが発行した当調査レポートでは、がん用バイオマーカーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、がんタイプ別分析、技術別分析、用途別分析、がん用バイオマーカーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
*** レポート概要(サマリー)***

The global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022. Over the years, the cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory and reimbursement scenario and the high capital investments required for biomarker development and validation are some factors expected to restrain the market.

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market. Increased understanding of the morphology of lung carcinogenesis, development of the high-throughput techniques for biomarker discovery, and increased focus on early detection of cancer are propelling the growth of this market.

North America (comprising the US and Canada) is expected to account for the largest share of the global cancer biomarkers market in 2017. The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. While the APAC region is expected to register the highest CAGR during the forecast period. The APAC cancer biomarkers market, particularly in China, Japan, and India is expected to witness high growth during the forecast period.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–40%, Tier 2–30%, and Tier 3–30%
• By Designation – Director level–18%, C-Level–27%, and Others–55%
• By Region – North America–50%, Europe–20%, Asia-Pacific–20%, and RoW–10%

Major players in this market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).

Research Coverage:
From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges). The report also offers market sizes and data on the growth of various segments of the industry. It focuses on emerging and high-growth segments, and high-growth regions. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output to remain successful.

Reasons to buy this report:
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on products offered by the top players in the cancer biomarkers market
• Product/Service Enhancement/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the cancer biomarkers market
• Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for profiling technologies across various regions
• Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the cancer biomarkers market
• Competitive Assessment: In-depth assessment of market ranking, strategies, products, and manufacturing capabilities of the leading players in the cancer biomarkers market

*** レポート目次(コンテンツ)***

TABLE OF CONTENTS

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.2.1 MARKETS COVERED 24
1.2.2 YEARS CONSIDERED FOR THE STUDY 24
1.3 CURRENCY 25
1.4 LIMITATIONS 25
1.5 STAKEHOLDERS 25

2 RESEARCH METHODOLOGY 26
2.1 MARKET SIZE ESTIMATION 27
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 30
2.2.1 SECONDARY SOURCES 31
2.2.1.1 Key Industry Insights 32
2.3 ASSUMPTIONS FOR THE STUDY 33

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHTS 38
4.1 CANCER BIOMARKERS: MARKET SNAPSHOT 38
4.2 ASIA PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY AND APPLICATION 39
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2017 VS. 2022 40
4.4 CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2015 TO 2022 40
4.5 CANCER BIOMARKERS MARKET, BY REGION 41

5 MARKET OVERVIEW 42
5.1 INTRODUCTION 42
5.1.1 DRIVERS 43
5.1.1.1 Technological advancements 43
5.1.1.2 Rising incidence of cancer 43
5.1.1.3 Increasing use of cancer biomarkers in drug discovery and development 44
5.1.1.4 Increasing research on cancer biomarkers 44
5.1.2 RESTRAINTS 45
5.1.2.1 Unfavorable regulatory and reimbursement scenario 45
5.1.2.2 High capital investment and low benefit-cost ratio 45
5.1.2.3 Technical issues related to sample collection and storage 46

5.1.3 OPPORTUNITIES 46
5.1.3.1 Personalized medicine 46
5.1.3.2 Companion diagnostics 46
5.1.3.3 Emerging economies 47
5.1.4 CHALLENGES 47
5.1.4.1 Proving the clinical validity and utility of biomarker-based tests 47

6 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE 48
6.1 INTRODUCTION 49
6.2 PROTEIN BIOMARKERS 50
6.3 GENETIC BIOMARKERS 52
6.3.1 LUNG CANCER 54
6.3.2 COLORECTAL CANCER 56
6.3.3 BREAST CANCER 57
6.3.4 PROSTATE CANCER 58
6.3.5 LEUKEMIA 59
6.4 OTHER CANCER BIOMARKERS 60

7 CANCER BIOMARKER MARKET, BY CANCER TYPE 63
7.1 INTRODUCTION 64
7.2 BREAST CANCER 65
7.3 LUNG CANCER 68
7.4 COLORECTAL CANCER 70
7.5 PROSTATE CANCER 72
7.6 NON-HODGKIN’S LYMPHOMA 74
7.7 MELANOMA 76
7.8 LEUKEMIA 78
7.9 THYROID CANCER 80
7.10 BLADDER CANCER 82
7.11 KIDNEY CANCER 84
7.12 OTHER CANCER TYPES 86

8 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY 89
8.1 INTRODUCTION 90
8.1.1 OMICS TECHNOLOGIES 91
8.1.2 PROTEOMICS 94
8.1.3 GENOMICS 96
8.1.3.1 Next-generation sequencing (NGS) 98
8.1.3.2 Polymerase chain reaction (PCR) 101
8.1.4 OTHER OMICS TECHNOLOGIES 103

8.2 IMAGING TECHNOLOGIES 106
8.2.1 ULTRASOUND 108
8.2.2 COMPUTED TOMOGRAPHY (CT) 110
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 113
8.2.4 POSITRON EMISSION TOMOGRAPHY (PET) 115
8.2.5 MAMMOGRAPHY 117
8.3 IMMUNOASSAYS 119
8.4 CYTOGENETICS 123
8.4.1 IN SITU HYBRIDIZATION (ISH) 125
8.4.2 OTHER CYTOGENETICS-BASED TESTS 128
8.5 BIOINFORMATICS 130

9 CANCER BIOMARKERS MARKET, BY APPLICATION 133
9.1 INTRODUCTION 134
9.2 DIAGNOSTICS 135
9.3 RESEARCH AND DEVELOPMENT 137
9.4 PROGNOSTICS 139
9.5 RISK ASSESSMENT 141
9.6 OTHER APPLICATIONS 143

10 CANCER BIOMARKERS MARKET, BY REGION 146
10.1 INTRODUCTION 147
10.2 NORTH AMERICA 148
10.2.1 US 153
10.2.2 CANADA 157
10.3 EUROPE 161
10.3.1 GERMANY 166
10.3.2 UK 170
10.3.3 FRANCE 174
10.3.4 ITALY 178
10.3.5 SPAIN 182
10.3.6 REST OF EUROPE (ROE) 186
10.4 ASIA PACIFIC 190
10.4.1 JAPAN 195
10.4.2 REST OF APAC 199
10.5 REST OF THE WORLD (ROW) 203

11 COMPETITIVE LANDSCAPE 208
11.1 MARKET RANKING ANALYSIS, 2016 208

12 COMPANY PROFILES 209
(BUSINESS OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*
12.1 THERMO FISHER SCIENTIFIC 209
12.2 BIO-RAD LABORATORIES 212
12.3 ROCHE DIAGNOSTICS 215
12.4 QIAGEN N.V. 218
12.5 ILLUMINA 222
12.6 GE HEALTHCARE 225
12.7 AGILENT TECHNOLOGIES 228
12.8 BIOMÉRIEUX SA 231
12.9 MERCK & CO. 234
12.10 ABBOTT LABORATORIES 237
12.11 BECTON, DICKINSON AND COMPANY 240
12.12 DANAHER CORPORATION 242
12.13 MYRIAD GENETICS 245
12.14 SYSMEX CORPORATION 248
12.15 HOLOGIC 251
12.16 QUEST DIAGNOSTICS 254
*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key relationships might not be captured in case of unlisted companies.

13 APPENDIX 257
13.1 INSIGHTS OF INDUSTRY EXPERTS 257
13.2 DISCUSSION GUIDE 258
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 264
13.5 AVAILABLE CUSTOMIZATIONS 266
13.6 RELATED REPORTS 266
13.7 AUTHOR DETAILS 267

LIST OF TABLES

TABLE 1 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 49
TABLE 2 GLOBAL PROTEIN CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 50
TABLE 3 NORTH AMERICA: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 51
TABLE 4 EUROPE: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 51
TABLE 5 ASIA PACIFIC: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 52
TABLE 6 GLOBAL GENETIC CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 53
TABLE 7 NORTH AMERICA: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 53
TABLE 8 EUROPE: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 54
TABLE 9 ASIA PACIFIC: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 54
TABLE 10 GLOBAL OTHER CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 61
TABLE 11 NORTH AMERICA: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 61
TABLE 12 EUROPE: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 62
TABLE 13 ASIA PACIFIC: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 62
TABLE 14 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 65
TABLE 15 GLOBAL BREAST CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 66
TABLE 16 NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 66
TABLE 17 EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 67
TABLE 18 ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 67
TABLE 19 GLOBAL LUNG CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 68
TABLE 20 NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 68
TABLE 21 EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 69
TABLE 22 ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 69
TABLE 23 GLOBAL COLORECTAL CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 70
TABLE 24 NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 70
TABLE 25 EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 71
TABLE 26 ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 71
TABLE 27 GLOBAL PROSTATE CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 72
TABLE 28 NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 73
TABLE 29 EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 73
TABLE 30 ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 73
TABLE 31 GLOBAL NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 74
TABLE 32 NORTH AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 75
TABLE 33 EUROPE: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 75
TABLE 34 ASIA PACIFIC: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET,
BY COUNTRY, 2015–2022 (USD MILLION) 75
TABLE 35 GLOBAL MELANOMA BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 76
TABLE 36 NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 76
TABLE 37 EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 77
TABLE 38 ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 77
TABLE 39 GLOBAL LEUKEMIA BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 78
TABLE 40 NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 78
TABLE 41 EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 79
TABLE 42 ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 79
TABLE 43 GLOBAL THYROID CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 80
TABLE 44 NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 80
TABLE 45 EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 81
TABLE 46 ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 81
TABLE 47 GLOBAL BLADDER CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 82
TABLE 48 NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 82
TABLE 49 EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 83
TABLE 50 ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 83
TABLE 51 GLOBAL KIDNEY CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 84
TABLE 52 NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 84
TABLE 53 EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 85
TABLE 54 ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 85
TABLE 55 GLOBAL OTHER CANCER BIOMARKERS MARKET, BY REGION,
2015–2022 (USD MILLION) 87
TABLE 56 NORTH AMERICA: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 87
TABLE 57 EUROPE: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 87
TABLE 58 ASIA PACIFIC: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 88
TABLE 59 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 91
TABLE 60 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE,
2015–2022 (USD MILLION) 92
TABLE 61 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION,
2015–2022 (USD MILLION) 92
TABLE 62 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY COUNTRY, 2015–2022 (USD MILLION) 92
TABLE 63 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY COUNTRY, 2015–2022 (USD MILLION) 93
TABLE 64 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES,
BY COUNTRY, 2015–2022 (USD MILLION) 93
TABLE 65 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2015–2022 (USD MILLION) 94
TABLE 66 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS,
BY COUNTRY, 2015–2022 (USD MILLION) 95
TABLE 67 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2015–2022 (USD MILLION) 95
TABLE 68 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2015–2022 (USD MILLION) 96
TABLE 69 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2015–2022 (USD MILLION) 96
TABLE 70 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION,
2015–2022 (USD MILLION) 97
TABLE 71 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS,
BY COUNTRY, 2015–2022 (USD MILLION) 97
TABLE 72 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2015–2022 (USD MILLION) 98
TABLE 73 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2015–2022 (USD MILLION) 98
TABLE 74 CANCER BIOMARKERS MARKET FOR NGS, BY REGION, 2015–2022 (USD MILLION) 99
TABLE 75 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY,
2015–2022 (USD MILLION) 99
TABLE 76 EUROPE: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY,
2015–2022 (USD MILLION) 100
TABLE 77 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY,
2015–2022 (USD MILLION) 100
TABLE 78 CANCER BIOMARKERS MARKET FOR PCR, BY REGION, 2015–2022 (USD MILLION) 101
TABLE 79 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY,
2015–2022 (USD MILLION) 102
TABLE 80 EUROPE: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY,
2015–2022 (USD MILLION) 102
TABLE 81 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY,
2015–2022 (USD MILLION) 103
TABLE 82 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2015–2022 (USD MILLION) 104
TABLE 83 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION) 104
TABLE 84 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES,
BY COUNTRY, 2015–2022 (USD MILLION) 105
TABLE 85 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION) 105
TABLE 86 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE,
2015–2022 (USD MILLION) 106
TABLE 87 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION,
2015–2022 (USD MILLION) 107
TABLE 88 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION) 107
TABLE 89 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES,
BY COUNTRY/REGION, 2015–2022 (USD MILLION) 108
TABLE 90 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES,
BY COUNTRY, 2015–2022 (USD MILLION) 108
TABLE 91 CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY REGION,
2015–2022 (USD MILLION) 109
TABLE 92 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR ULTRASOUND,
BY COUNTRY, 2015–2022 (USD MILLION) 109
TABLE 93 EUROPE: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY,
2015–2022 (USD MILLION) 110
TABLE 94 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY, 2015–2022 (USD MILLION) 110
TABLE 95 CANCER BIOMARKERS MARKET FOR CT, BY REGION, 2015–2022 (USD MILLION) 111
TABLE 96 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY,
2015–2022 (USD MILLION) 111
TABLE 97 EUROPE: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY,
2015–2022 (USD MILLION) 112
TABLE 98 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY,
2015–2022 (USD MILLION) 112
TABLE 99 CANCER BIOMARKERS MARKET FOR MRI, BY REGION, 2015–2022 (USD MILLION) 113
TABLE 100 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY,
2015–2022 (USD MILLION) 114
TABLE 101 EUROPE: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY,
2015–2022 (USD MILLION) 114
TABLE 102 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY,
2015–2022 (USD MILLION) 115
TABLE 103 CANCER BIOMARKERS MARKET FOR PET, BY REGION, 2015–2022 (USD MILLION) 115
TABLE 104 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY,
2015–2022 (USD MILLION) 116
TABLE 105 EUROPE: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY,
2015–2022 (USD MILLION) 116
TABLE 106 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY,
2015–2022 (USD MILLION) 117
TABLE 107 CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY REGION,
2015–2022 (USD MILLION) 117
TABLE 108 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY,
BY COUNTRY, 2015–2022 (USD MILLION) 118
TABLE 109 EUROPE: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015–2022 (USD MILLION) 118
TABLE 110 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015–2022 (USD MILLION) 119
TABLE 111 CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION,
2015–2022 (USD MILLION) 121
TABLE 112 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2015–2022 (USD MILLION) 121
TABLE 113 EUROPE: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 122
TABLE 114 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 122
TABLE 115 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY REGION,
2015–2022 (USD MILLION) 123
TABLE 116 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR CYTOGENETICS,
BY COUNTRY, 2015–2022 (USD MILLION) 124
TABLE 117 EUROPE: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015–2022 (USD MILLION) 124
TABLE 118 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015–2022 (USD MILLION) 125
TABLE 119 CANCER BIOMARKERS MARKET FOR ISH, BY REGION, 2015–2022 (USD MILLION) 126
TABLE 120 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY,
2015–2022 (USD MILLION) 126
TABLE 121 EUROPE: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY,
2015–2022 (USD MILLION) 127
TABLE 122 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY,
2015–2022 (USD MILLION) 127
TABLE 123 CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS,
BY REGION, 2015–2022 (USD MILLION) 128
TABLE 124 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015–2022 (USD MILLION) 129
TABLE 125 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015–2022 (USD MILLION) 129
TABLE 126 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015–2022 (USD MILLION) 130
TABLE 127 GLOBAL CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY REGION, 2015–2022 (USD MILLION) 131
TABLE 128 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS,
BY COUNTRY, 2015–2022 (USD MILLION) 131
TABLE 129 EUROPE: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY COUNTRY, 2015–2022 (USD MILLION) 132
TABLE 130 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS,
BY COUNTRY, 2015–2022 (USD MILLION) 132
TABLE 131 GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 134
TABLE 132 GLOBAL CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION,
2015–2022 (USD MILLION) 135
TABLE 133 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS,
BY COUNTRY, 2015–2022 (USD MILLION) 136
TABLE 134 EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY,
2015–2022 (USD MILLION) 136
TABLE 135 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION) 136
TABLE 136 GLOBAL CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT,
BY REGION, 2015–2022 (USD MILLION) 137
TABLE 137 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION) 138
TABLE 138 EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT,
BY COUNTRY, 2015–2022 (USD MILLION) 138
TABLE 139 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION) 138
TABLE 140 GLOBAL CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY REGION,
2015–2022 (USD MILLION) 139
TABLE 141 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROGNOSTICS,
BY COUNTRY, 2015–2022 (USD MILLION) 140
TABLE 142 EUROPE: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION) 140
TABLE 143 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION) 140
TABLE 144 GLOBAL CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2015–2022 (USD MILLION) 141
TABLE 145 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT,
BY COUNTRY, 2015–2022 (USD MILLION) 142
TABLE 146 EUROPE: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2015–2022 (USD MILLION) 142
TABLE 147 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT,
BY COUNTRY, 2015–2022 (USD MILLION) 142
TABLE 148 GLOBAL CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2015–2022 (USD MILLION) 143
TABLE 149 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2015–2022 (USD MILLION) 144
TABLE 150 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2015–2022 (USD MILLION) 144
TABLE 151 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2015–2022 (USD MILLION) 145
TABLE 152 GLOBAL CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION) 148
TABLE 153 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 150
TABLE 154 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 150
TABLE 155 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 151
TABLE 156 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION) 151
TABLE 157 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 151
TABLE 158 NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 152
TABLE 159 NORTH AMERICA: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 152
TABLE 160 NORTH AMERICA: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 153
TABLE 161 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 153
TABLE 162 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 154
TABLE 163 US: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 155
TABLE 164 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 155
TABLE 165 US: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 155
TABLE 166 US: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 156
TABLE 167 US: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 156
TABLE 168 US: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 156
TABLE 169 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 157
TABLE 170 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 158
TABLE 171 CANADA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 158
TABLE 172 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 159
TABLE 173 CANADA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 159
TABLE 174 CANADA: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 159
TABLE 175 CANADA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 160
TABLE 176 CANADA: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 160
TABLE 177 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 161
TABLE 178 EUROPE :CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 163
TABLE 179 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 163
TABLE 180 EUROPE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 164
TABLE 181 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 164
TABLE 182 EUROPE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 164
TABLE 183 EUROPE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 165
TABLE 184 EUROPE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 165
TABLE 185 EUROPE: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 165
TABLE 186 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 166
TABLE 187 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 167
TABLE 188 GERMANY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 167
TABLE 189 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 168
TABLE 190 GERMANY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 168
TABLE 191 GERMANY: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 168
TABLE 192 GERMANY: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 169
TABLE 193 GERMANY: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 169
TABLE 194 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 170
TABLE 195 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 171
TABLE 196 UK: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 171
TABLE 197 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 172
TABLE 198 UK: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 172
TABLE 199 UK: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 172
TABLE 200 UK: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 173
TABLE 201 UK: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 173
TABLE 202 UK: CANCER BIOMARKERS MARKET, BY APPLICATION ,
2015–2022 (USD MILLION) 174
TABLE 203 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 175
TABLE 204 FRANCE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 175
TABLE 205 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 176
TABLE 206 FRANCE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 176
TABLE 207 FRANCE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 176
TABLE 208 FRANCE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 177
TABLE 209 FRANCE: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 177
TABLE 210 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 178
TABLE 211 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 179
TABLE 212 ITALY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 179
TABLE 213 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 180
TABLE 214 ITALY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 180
TABLE 215 ITALY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 180
TABLE 216 ITALY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 181
TABLE 217 ITALY: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 181
TABLE 218 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 182
TABLE 219 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 183
TABLE 220 SPAIN: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2022 (USD MILLION) 183
TABLE 221 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 184
TABLE 222 SPAIN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 184
TABLE 223 SPAIN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 184
TABLE 224 SPAIN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 185
TABLE 225 SPAIN: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 185
TABLE 226 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 186
TABLE 227 ROE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 186
TABLE 228 ROE: CANCER BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION) 187
TABLE 229 ROE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 187
TABLE 230 ROE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 188
TABLE 231 ROE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 188
TABLE 232 ROE: IMAGING TECHNOLOGIES MARKET, 2015–2022 (USD MILLION) 188
TABLE 233 ROE: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 189
TABLE 234 ROE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 189
TABLE 235 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 192
TABLE 236 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 192
TABLE 237 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 193
TABLE 238 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION) 193
TABLE 239 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 193
TABLE 240 ASIA PACIFIC: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 194
TABLE 241 ASIA PACIFIC: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 194
TABLE 242 ASIA PACIFIC: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 194
TABLE 243 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 195
TABLE 244 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 196
TABLE 245 JAPAN: CANCER BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION) 196
TABLE 246 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 197
TABLE 247 JAPAN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 197
TABLE 248 JAPAN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 197
TABLE 249 JAPAN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 198
TABLE 250 JAPAN: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 198
TABLE 251 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 199
TABLE 252 REST OF APAC: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 200
TABLE 253 REST OF APAC: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2015–2020 (USD MILLION) 201
TABLE 254 REST OF APAC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION) 201
TABLE 255 REST OF APAC: OMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 201
TABLE 256 REST OF APAC: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 202
TABLE 257 REST OF APAC: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2015–2022 (USD MILLION) 202
TABLE 258 REST OF APAC: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 202
TABLE 259 REST OF APAC: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 203
TABLE 260 ROW: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2015–2022 (USD MILLION) 204
TABLE 261 ROW: CANCER BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION) 205
TABLE 262 ROW: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2015–2022 (USD MILLION) 205
TABLE 263 ROW: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 205
TABLE 264 ROW: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 206
TABLE 265 ROW: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION) 206
TABLE 266 ROW: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION) 206
TABLE 267 ROW: CANCER BIOMARKERS MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 207
TABLE 268 RANK OF COMPANIES IN THE GLOBAL CANCER BIOMARKERS MARKET, 2016 208


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 26
FIGURE 2 BOTTOM-UP APPROACH 28
FIGURE 3 TOP-DOWN APPROACH 28
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 29
FIGURE 5 DATA TRIANGULATION 30
FIGURE 6 CANCER BIOMARKER MARKET, BY CANCER TYPE, 2017 VS. 2022 (USD MILLION) 34
FIGURE 7 CANCER BIOMARKER MARKET, BY BIOMARKER TYPE,
2017 VS. 2022 (USD MILLION) 35
FIGURE 8 CANCER BIOMARKER MARKET, BY APPLICATION, 2017 VS. 2022 (USD MILLION) 36
FIGURE 9 CANCER BIOMARKER MARKET, BY PROFILING TECHNOLOGY,
2017 VS. 2022 (USD MILLION) 36
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE CANCER BIOMARKER MARKET 37
FIGURE 11 TECHNOLOGICAL ADVANCEMENT IS A MAJOR DRIVER FOR THE CANCER BIOMARKERS MARKET GROWTH IN 2017 38
FIGURE 12 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 42
FIGURE 13 GENETIC BIOMARKERS TO REGISTER THE HIGHEST CAGR IN THE FORECAST PERIOD 49
FIGURE 14 MUTATION RATE OF CELL SURFACE RECEPTOR BIOMARKERS IN BREAST TUMOR 57
FIGURE 15 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE 64
FIGURE 16 OMICS TECHNOLOGIES WILL CONTINUE TO DOMINATE THE GLOBAL CANCER BIOMARKERS MARKET IN 2022 90
FIGURE 17 DIAGNOSTICS APPLICATION SEGMENT TO DOMINATE THE CANCER BIOMARKERS MARKET IN 2017 134
FIGURE 18 CANCER BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT (2017–2022) 147
FIGURE 19 NORTH AMERICA MARKET SNAPSHOT 149
FIGURE 20 EUROPE MARKET SNAPSHOT 162
FIGURE 21 ASIA PACIFIC MARKET SNAPSHOT 191
FIGURE 22 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016) 209
FIGURE 23 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2016) 212
FIGURE 24 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2016) 215
FIGURE 25 QIAGEN N.V.: COMPANY SNAPSHOT (2016) 218
FIGURE 26 ILLUMINA: COMPANY SNAPSHOT (2016) 222
FIGURE 27 GE HEALTHCARE: COMPANY SNAPSHOT (2016) 225
FIGURE 28 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2016) 228
FIGURE 29 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2016) 231
FIGURE 30 MERCK & CO.INC.: COMPANY SNAPSHOT (2016) 234
FIGURE 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016) 237
FIGURE 32 BECTON, DICKINSON AND COMPANY : COMPANY SNAPSHOT (2016) 240
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2016) 242
FIGURE 34 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2016) 245
FIGURE 35 SYSMEX CORPORATION: COMPANY SNAPSHOT (2016) 248
FIGURE 36 HOLOGIC: COMPANY SNAPSHOT (2016) 251
FIGURE 37 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2016) 254


*** レポートのキーワード ***

がん用バイオマーカー、タンパク質バイオマーカー、遺伝子バイオマーカー、癌診断、バイオマーカー技術

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MAM-MD-5627 )"がん用バイオマーカーの世界市場予測(~2022年):タンパク質バイオマーカー、遺伝子バイオマーカー" (英文:Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。